Cardiovascular disease in survivors of childhood cancer

Neha Bansal, Shahnawaz M. Amdani, Kelley K. Hutchins, Steven E. Lipshultz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

Original languageEnglish (US)
Pages (from-to)628-638
Number of pages11
JournalCurrent Opinion in Pediatrics
Volume30
Issue number5
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Anthracyclines
Cardiovascular Diseases
Neoplasms
Dexrazoxane
Drug Therapy
Cardiotoxicity

Keywords

  • Anthracycline
  • Cardio-oncology
  • Cardiotoxicity
  • Childhood cancer
  • Survivorship

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Cardiovascular disease in survivors of childhood cancer. / Bansal, Neha; Amdani, Shahnawaz M.; Hutchins, Kelley K.; Lipshultz, Steven E.

In: Current Opinion in Pediatrics, Vol. 30, No. 5, 01.01.2018, p. 628-638.

Research output: Contribution to journalArticle

Bansal, Neha ; Amdani, Shahnawaz M. ; Hutchins, Kelley K. ; Lipshultz, Steven E. / Cardiovascular disease in survivors of childhood cancer. In: Current Opinion in Pediatrics. 2018 ; Vol. 30, No. 5. pp. 628-638.
@article{383775809c0f430a924eaa56d81f4a4a,
title = "Cardiovascular disease in survivors of childhood cancer",
abstract = "A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.",
keywords = "Anthracycline, Cardio-oncology, Cardiotoxicity, Childhood cancer, Survivorship",
author = "Neha Bansal and Amdani, {Shahnawaz M.} and Hutchins, {Kelley K.} and Lipshultz, {Steven E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/MOP.0000000000000675",
language = "English (US)",
volume = "30",
pages = "628--638",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cardiovascular disease in survivors of childhood cancer

AU - Bansal, Neha

AU - Amdani, Shahnawaz M.

AU - Hutchins, Kelley K.

AU - Lipshultz, Steven E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

AB - A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.

KW - Anthracycline

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Childhood cancer

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=85056496846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056496846&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000675

DO - 10.1097/MOP.0000000000000675

M3 - Article

C2 - 30124579

AN - SCOPUS:85056496846

VL - 30

SP - 628

EP - 638

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 5

ER -